

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

#### **RESIGNATION OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board (“**Board**”) of directors (“**Directors**”, and each a “**Director**”) of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Lai Kwok Wa (“**Mr. Lai**”) has resigned as (i) the company secretary of the Company (“**Company Secretary**”), (ii) the authorised representative of the Company (“**Authorised Representative**”) under Rule 3.05 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and (iii) the authorised representative of the Company for the acceptance of service of process and notices in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19.05(2) of the Listing Rules (“**Process Agent**”), in each case, with effect from 11 July 2023, due to his intention to pursue his other personal affairs.

Mr. Lai has confirmed that he has no disagreement with the Board and there is no other matter related to his resignation which needs to be brought to the attention of the shareholders of the Company or of the Stock Exchange.

## **APPOINTMENT OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The Board further announces that Mr. Ng Yat Sing (“**Mr. Ng**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent all with effect from 11 July 2023.

Mr. Ng has over 10 years of experience in the field of auditing and accounting and previously worked in the audit department of an international accounting firm in Hong Kong and in the finance department of a company listed in Hong Kong before joining the Company. He joined the Group in October 2019 and is the Financial Controller of the Group with effect from 11 July 2023. Mr. Ng is a holder of a Bachelor of Business (Accounting) degree from Australian Catholic University. He is a member of Hong Kong Institute of Certified Public Accountants.

The Board takes this opportunity to express its sincere gratitude to Mr. Lai for his valuable contribution to the Company during his tenure of office and also extends its welcome to Mr. Ng on his appointment.

On behalf of the Board

**New Ray Medicine International Holding Limited**

**Wang Qiuqin**

*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, 11 July 2023

*As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*